NEW YORK (GenomeWeb) – Overall survival analysis of EGFR mutation subpopulations in two trials involving Boehringer Ingelheim's Gilotrif (afatinib) shows that non-Asian patients with Del19 mutated non-small cell lung cancer tumors live significantly longer – a median of an additional year – on Gilotrif compared to chemotherapy.
Meanwhile, researchers led by Massachusetts General Hospital's Lecia Sequist didn't observe similar survival advantages in non-Asian patients with L858R mutations when they received Gilotrif compared to chemotherapy.